ILK and chronic myelogenous leukemia, BCR-ABL1 positive: Collectively, these studies demonstrate the importance of ILK in controlling LSCs in the bone marrow niche to promote CML and demonstrate that specific targeting of ILK may be beneficial in providing clinical impact in the setting of TKI-resistant disease.